2-MERCAPTOETHANESULFONIC ACID
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | IFEX/MESNEX KIT | — | 1987-08-14 | fda.gov ↗ |
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04449536 | Nov 2020 → Oct 2021 | obesity disorder | University of Oslo | Completed | No outcome recorded |
| Phase 1 | NCT02660281 | Oct 2015 → Oct 2019 | immunodeficiency disease, myelofibrosis, plasma cell myeloma | University of Rochester | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00167219 | Nov 1999 → Jul 2022 | juvenile myelomonocytic leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/2 | NCT00179816 | Apr 1999 → Sep 2012 | Ewing sarcoma, Hodgkins lymphoma, germ cell tumor, hepatoblastoma +1 | Ann & Robert H Lurie Children's Hospital of Chicago | Unknown | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT01333605 | Apr 2011 → Apr 2014 | Hodgkins lymphoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT01205503 | Sep 2010 → Aug 2012 | breast cancer, non-Hodgkin lymphoma | Mara Chambers | Completed | Met primary |
| Phase 2 | NCT00774332 | Jun 2006 | acute lymphoblastic leukemia | Cooperative Study Group A for Hematology | Unknown | No outcome recorded |
| Phase 2 | NCT00126191 | Jul 2005 → Dec 2009 | Burkitt lymphoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00223548 | Oct 2002 → Dec 2004 | chronic renal failure syndrome | University of Ulm | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04486391 | Dec 2020 → Oct 2025 | classic Hodgkin lymphoma | BeiGene | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00002565 | May 1994 → Feb 2007 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01501149 | Jan 2011 → Dec 2015 | extranodal nasal NK/T cell lymphoma | Mingzhi Zhang | Unknown | Met primary |
| Phase not applicable4 trials | ||||||
| — | NCT05882604 | Mar 2023 → Mar 2024 | temporomandibular joint disorder | Tanta University | Completed | No outcome recorded |
| — | NCT05041686 | May 2019 → Feb 2021 | acute cholecystitis | AuXin Surgery SA | Completed | No outcome recorded |
| — | NCT01505569 | Oct 2011 → Feb 2024 | Ewing sarcoma, atypical teratoid rhabdoid tumor, germ cell tumor, hepatoblastoma +6 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| — | NCT00758667 | Jan 2005 → Aug 2008 | breast disorder | Vanderbilt University | Terminated | No outcome recorded |
| Comparator or background therapy217 trials | ||||||
| Phase 0 | NCT06942039 Background | Sep 2025 → Dec 2030 expected | atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 | C17 Council | Recruiting | No outcome recorded |
| Phase 0 | NCT05438667 Background | Jun 2023 → Jun 2026 | malignant pancreatic neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Terminated | No outcome recorded |
| Phase 0 | NCT04947501 Background | Jun 2021 → Jun 2026 overdue | childhood malignant neoplasm, neuroblastoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02212574 Background | Apr 2017 → Nov 2018 | medulloblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 0 | NCT01331590 Background | Jul 2011 → Oct 2014 | precursor lymphoblastic lymphoma/leukemia | Washington University School of Medicine | Completed | No outcome recorded |
| Show all 217 trials opens the full record — a long page | ||||||
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 235 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-MERCAPTOETHANESULFONIC ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | Coenzyme m sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | D 7093 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | Mercaptoethane Sulfonate | “Mesna Mercaptoethane Sulfonate, NSC-113891” NCT00002691 ↗3“Mesna Mercaptoethane sulfonate, NSC-113891” NCT00002704 ↗ “Mesna Mercaptoethane sulfonate, NSC-113891” NCT00002549 ↗ “Mesna Mercaptoethane sulfonate” NCT00002565 ↗ |
| Known as | Mesna | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗230“Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours...” NCT02856997 ↗ “R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate...” NCT01854372 ↗ “Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between...” NCT03651375 ↗ “It is based on the property of the drug mesna (Sodium 2-mercaptoethane sulfonate) to cleave the disulfide bonds responsible for the adherence of pathological tissues and for...” NCT05041686 ↗ “Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA,...” NCT07187960 ↗ “Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure.” NCT00223548 ↗ “MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.” NCT00578539 ↗ “AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W” NCT04699214 ↗ “* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.” NCT01696669 ↗ “Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after.” NCT06027957 ↗ |
| Known as | Mesna - sodium 2-mercapto-ethanesulphonate | “Mesna - sodium 2-mercapto-ethanesulphonate” NCT00093509 ↗ |
| Known as | mesna: Mesnex(R) | “mesna: Mesnex(R)” NCT00640796 ↗ |
| Known as | Mesnex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | Mistabron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1098319 ↗ |
| Known as | NSC-113891 | “Mesna Mercaptoethane Sulfonate, NSC-113891” NCT00002691 ↗3“Mesna Mercaptoethane sulfonate, NSC-113891” NCT00002704 ↗ “and Mesna, NSC-113891.” NCT00001300 ↗ “Mesna, NSC-113891” NCT00002510 ↗ |
| Known as | sodium 2-mercaptoethanesulfonate | “This study evaluated sodium-2-mercaptoethane sulfonate (Mesna) co-administration with doxorubicin to reduce doxorubicin-induced plasma protein oxidation and resultant cascade...” PMID 25909710 ↗ Apr 20152“MESNA (sodium 2-mercaptoethanesulfonate) was approved several years ago and marketed in several formulations as a mucolytic agent in the respiratory field, since it breaks the...” NCT05882604 ↗ “It is based on the property of the drug mesna (Sodium 2-mercaptoethane sulfonate) to cleave the disulfide bonds responsible for the adherence of pathological tissues and for...” NCT05041686 ↗ |
| Known as | Uromitexan | “Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks” NCT00658580 ↗ |
| Modality | Small molecule | “Mesna is a synthetic sulfhydryl (thiol) compound.” NCT03849651 ↗ |
| Route | Intravenous | “Given IV” NCT00002816 ↗ |